Therapy for cancer-related thromboembolism

Seminars in Oncology

Volumn 41, Issue 3, 2014, Pages 319-338

  Frere, Corinne ^a,b   Debourdeau, Philippe ^c   Hij, Adrian ^d   Cajfinger, Francis ^e   Onan, Michel N'Guessan ^f   Panicot Dubois, Laurence ^b   Dubois, Christophe ^b   Farge, Dominique ^d,g  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT SAINTE CATHERINE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; APIXABAN; ASPARAGINASE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; FONDAPARINUX; HEPARIN; LENALIDOMIDE; RIVAROXABAN; THALIDOMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR RISK; CATHETER THROMBOSIS; CAUSE OF DEATH; CENTRAL VENOUS CATHETER; CHILDHOOD LEUKEMIA; FOLLOW UP; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LUNG EMBOLISM; PALLIATIVE THERAPY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT DURATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; HUMANS; NEOPLASMS; THROMBOEMBOLISM;

EID: 84904191344     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.04.005     Document Type: Article

References (155)

1. M. Mandalà, A. Falanga, A. Piccioli, P. Prandoni, E.M. Pogliani, and R. Labianca et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM) Crit Rev Oncol Hematol 59 2006 194 204
2. G.H. Lyman, A.A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, and M. Jahanzeb et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 2007 5490 5505
3. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed) Chest 133 Suppl 6 2008 381S 453S
4. P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, and M.-C. Douard et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group Ann Oncol 20 2009 1459 1471
5. M. Mandalà, A. Falanga, F. Roila ESMO Guidelines Working Group Management of venous thromboembolism in cancer patients: ESMO clinical recommendations Ann Oncol 20 Suppl 4 2009 182 184
6. D. Farge, L. Bosquet, D. Kassab-Chahmi, P. Mismetti, I. Elalamy, and G. Meyer et al. French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group Crit Rev Oncol Hematol 73 2010 31 46
7. M. Mandalà, A. Falanga, F. Roila ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 22 Suppl 6 2011 (vi85-92)
8. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 141 Suppl 2 2012 419S 494SS
9. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Venous Thromboembolic Disease version 2.2013. Available at: http://www.nccn.org. Accessed March 1, 2014.
10. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, and E.P. Balaban et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 31 2013 2189 2204
11. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, and B. Brenner et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J Thromb Haemost 11 2013 56 70
12. P. Debourdeau, D. Farge, M. Beckers, C. Baglin, R.M. Bauersachs, and B. Brenner et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer J Thromb Haemost 11 2013 71 80
13. N. Levitan, A. Dowlati, S.C. Remick, H.I. Tahsildar, L.D. Sivinski, and R. Beyth et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291
14. J.A. Heit, W.M. O'Fallon, T.M. Petterson, C.M. Lohse, M.D. Silverstein, and D.N. Mohr et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study Arch Intern Med 162 2002 1245 1248
15. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93:298-305.
16. F.A. Spencer, D. Lessard, C. Emery, G. Reed, and R.J. Goldberg Venous thromboembolism in the outpatient setting Arch Intern Med 167 2007 1471 1475
17. G. Gussoni, S. Frasson, M. La Regina, P. Di Micco, and M. Monreal RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry Thromb Res 131 2013 24 30
18. S.K. Braekkan, K.H. Borch, E.B. Mathiesen, I. Njølstad, T. Wilsgaard, and J.-B. Hansen Body height and risk of venous thromboembolism: The Tromsø Study Am J Epidemiol 171 2010 1109 1115
19. J.W. Blom, C.J.M. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715 722
20. A.A. Khorana, C.W. Francis, E. Culakova, R.I. Fisher, N.M. Kuderer, and G.H. Lyman Thromboembolism in hospitalized neutropenic cancer patients J Clin Oncol 24 2006 484 490
21. A. Falanga Thrombophilia in cancer Semin Thromb Hemost 31 2005 104 110
22. D. Imberti, G. Agnelli, W. Ageno, M. Moia, G. Palareti, and R. Pistelli et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry Haematologica 93 2008 273 278
23. I.A. Naess, S.C. Christiansen, P. Romundstad, S.C. Cannegieter, F.R. Rosendaal, and J. Hammerstrøm Incidence and mortality of venous thrombosis: a population-based study J Thromb Haemost 5 2007 692 699
24. A.J. Walker, T.R. Card, J. West, C. Crooks, and M.J. Grainge Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases Eur J Cancer 49 2013 1404 1413
25. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients Cancer 110 2007 2339 2346
26. P.D. Stein, A. Beemath, F.A. Meyers, E. Skaf, J. Sanchez, and R.E. Olson Incidence of venous thromboembolism in patients hospitalized with cancer Am J Med 119 2006 60 68
27. J.F. Timp, S.K. Braekkan, H.H. Versteeg, and S.C. Cannegieter Epidemiology of cancer-associated venous thrombosis Blood 122 2013 1712 1723
28. S. Sallah, J.Y. Wan, and N.P. Nguyen Venous thrombosis in patients with solid tumors: determination of frequency and characteristics Thromb Haemost 87 2002 575 579
29. R. Vormittag, R. Simanek, C. Ay, D. Dunkler, P. Quehenberger, and C. Marosi et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study Arterioscler Thromb Vasc Biol 29 2009 2176 2181
30. H.K. Chew, T. Wun, D. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 2006 458 464
31. A.A. Khorana, M. Dalal, J. Lin, and G.C. Connolly Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States Cancer 119 2013 648 655
32. R.A. Moore, N. Adel, E. Riedel, M. Bhutani, D.R. Feldman, and N.E. Tabbara et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis J Clin Oncol 29 2011 3466 3473
33. G. Agnelli, G. Gussoni, C. Bianchini, M. Verso, M. Mandalà, and L. Cavanna et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Lancet Oncol 10 2009 943 949
34. G. Agnelli, D.J. George, A.K. Kakkar, W. Fisher, M.R. Lassen, and P. Mismetti et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer N Engl J Med 366 2012 601 609
35. F. Horsted, J. West, and M.J. Grainge Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis PLoS Med 2012 9
36. G. Piazza, A.F. Rao, T.N. Nguyen, A.C. Seger, B. Hohlfelder, and J. Fanikos et al. Venous thromboembolism in hospitalized patients with active cancer Clin Appl Thromb Off J Int Acad Clin Appl Thromb 19 2013 469 475
37. G. Piazza Venous thromboembolism and cancer Circulation 128 2013 2614 2618
38. P. Prandoni, A.W. Lensing, A. Cogo, S. Cuppini, S. Villalta, and M. Carta et al. The long-term clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1 7
39. A.Y.Y. Lee, and M.N. Levine Venous thromboembolism and cancer: risks and outcomes Circulation 107 2003 (I-17-I-21)
40. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J Thromb Haemost 5 2007 632 634
41. H.T. Sørensen, L. Mellemkjaer, J.H. Olsen, and J.A. Baron Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 2000 1846 1850
42. P. Prandoni, A.W.A. Lensing, A. Piccioli, E. Bernardi, P. Simioni, and B. Girolami et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
43. J. Trujillo-Santos, J.A. Nieto, G. Tiberio, A. Piccioli, P. Di Micco, and P. Prandoni et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry Thromb Haemost 100 2008 435 439
44. M.L. Louzada, M. Carrier, A. Lazo-Langner, V. Dao, M.J. Kovacs, and T.O. Ramsay et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism Circulation 126 2012 448 454
45. A.A. Khorana, C. O'Connell, G. Agnelli, H.A. Liebman, and A.Y.Y. Lee Subcommittee on Hemostasis and Malignancy of the SSC of the ISTH. Incidental venous thromboembolism in oncology patients J Thromb Haemost 10 2012 2602 2604
46. C.L. O'Connell, W.D. Boswell, V. Duddalwar, A. Caton, L.S. Mark, and C. Vigen et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance J Clin Oncol 24 2006 4928 4932
47. M. Di Nisio, N. Ferrante, M. De Tursi, S. Iacobelli, F. Cuccurullo, and H.R. Büller et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy Thromb Haemost 104 2010 1049 1054
48. C. O'Connell, P. Razavi, M. Ghalichi, S. Boyle, S. Vasan, and L. Mark et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning J Thromb Haemost 9 2011 305 311
49. G.C. Connolly, L. Menapace, S. Safadjou, C.W. Francis, and A.A. Khorana Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients Clin Lung Cancer 14 2013 713 718
50. L.A. Menapace, D.R. Peterson, A. Berry, T. Sousou, and A.A. Khorana Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer Thromb Haemost 106 2011 371 378
51. M. Sahut D'Izarn, A. Caumont Prim, B. Planquette, M.P. Revel, P. Avillach, and G. Chatellier et al. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study J Thromb Haemost 10 2012 2032 2038
52. Callejas MF, Errázuriz JI, Castillo F, Otárola C, Riquelme C, Ortega C, et al. Incidental venous thromboembolism detected by PET-CT in patients with cancer: Prevalence and impact on survival rate. Thromb Res. Epub 2014 Feb 9. 10.1016/j.thromres.2014.02.005. Available from: http://www. sciencedirect.com/science/article/pii/S004938481400084X
53. A.A. Khorana, C.W. Francis, E. Culakova, and G.H. Lyman Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study Cancer 104 2005 2822 2829
54. A.A. Khorana, and G.C. Connolly Assessing risk of venous thromboembolism in the patient with cancer J Clin Oncol 27 2009 4839 4847
55. G. Numico, O. Garrone, V. Dongiovanni, N. Silvestris, I. Colantonio, and G. Di Costanzo et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine Cancer 103 2005 994 999
56. V. Kyriazi, and E. Theodoulou Assessing the risk and prognosis of thrombotic complications in cancer patients Arch Pathol Lab Med 137 2013 1286 1295
57. A. Alcalay, T. Wun, V. Khatri, H.K. Chew, D. Harvey, and H. Zhou et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 2006 1112 1118
58. D.P. Cronin-Fenton, F. Søndergaard, L.A. Pedersen, J.P. Fryzek, K. Cetin, and J. Acquavella et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006 Br J Cancer 103 2010 947 953
59. G. Agnelli, G. Bolis, L. Capussotti, R.M. Scarpa, F. Tonelli, and E. Bonizzoni et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project Ann Surg 243 2006 89 95
60. H.K. Chew, A.M. Davies, T. Wun, D. Harvey, H. Zhou, and R.H. White The incidence of venous thromboembolism among patients with primary lung cancer J Thromb Haemost 6 2008 601 608
61. K. Kröger, D. Weiland, C. Ose, N. Neumann, S. Weiss, and C. Hirsch et al. Risk factors for venous thromboembolic events in cancer patients Ann Oncol 17 2006 297 303
62. S.R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
63. F.A. Scappaticci, J.R. Skillings, S.N. Holden, H.-P. Gerber, K. Miller, and F. Kabbinavar et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
64. C.C. McDonald, F.E. Alexander, B.W. Whyte, A.P. Forrest, and H.J. Stewart Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group BMJ 311 1995 977 980
65. K.I. Pritchard, A.H. Paterson, N.A. Paul, B. Zee, S. Fine, and J. Pater Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group J Clin Oncol 14 1996 2731 2737
66. J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, and J. Sandercock et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 2006 708 714
67. C.L. Bennett, S.M. Silver, B. Djulbegovic, A.T. Samaras, C.A. Blau, and K.J. Gleason et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia JAMA 299 2008 914 924
68. M. Verso, and G. Agnelli Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 2003 3665 3675
69. A.Y.Y. Lee, and P.W. Kamphuisen Epidemiology and prevention of catheter-related thrombosis in patients with cancer J Thromb Haemost 10 2012 1491 1499
70. F. Dentali, M. Gianni, G. Agnelli, and W. Ageno Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis J Thromb Haemost 6 2008 70 75
71. R. Alikhan, A.T. Cohen, S. Combe, M.M. Samama, L. Desjardins, and A. Eldor et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study Arch Intern Med 164 2004 963 968
72. R.H. White, H. Zhou, and P.S. Romano Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures Thromb Haemost 90 2003 446 455
73. A.A. Khorana, M.B. Streiff, D. Farge, M. Mandala, P. Debourdeau, and F. Cajfinger et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action J Clin Oncol 27 2009 4919 4926
74. A. Young, O. Chapman, C. Connor, C. Poole, P. Rose, and A.K. Kakkar Thrombosis and cancer Nat Rev Clin Oncol 9 2012 437 449
75. V.Q. Trinh, P.I. Karakiewicz, J. Sammon, M. Sun, S. Sukumar, and M.-K. Gervais et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care JAMA Surg 149 2014 43 49
76. I. Pabinger, J. Thaler, and C. Ay Biomarkers for prediction of venous thromboembolism in cancer Blood 122 2013 2011 2018
77. R. Simanek, R. Vormittag, C. Ay, G. Alguel, D. Dunkler, and I. Schwarzinger et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) J Thromb Haemost JTH 8 2010 114 120
78. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907
79. M.T. Stender, J.B. Frøkjaer, T.B. Larsen, S. Lundbye-Christensen, and O. Thorlacius-Ussing Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up Dis Colon Rectum 52 2009 446 451
80. C. Ay, R. Vormittag, D. Dunkler, R. Simanek, A.-L. Chiriac, and J. Drach et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study J Clin Oncol 27 2009 4124 4129
81. C. Ay, D. Dunkler, C. Marosi, A.-L. Chiriac, R. Vormittag, and R. Simanek et al. Prediction of venous thromboembolism in cancer patients Blood 116 2010 5377 5382
82. C. Ay, R. Simanek, R. Vormittag, D. Dunkler, G. Alguel, and S. Koder et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) Blood 112 2008 2703 2708
83. I. Pabinger, and C. Ay Biomarkers and venous thromboembolism Arterioscler Thromb Vasc Biol 29 2009 332 336
84. C. Ay, D. Dunkler, R. Simanek, J. Thaler, S. Koder, and C. Marosi et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study J Clin Oncol 29 2011 2099 2103
85. J.I. Zwicker, H.A. Liebman, D. Neuberg, R. Lacroix, K.A. Bauer, and B.C. Furie et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy Clin Cancer Res 15 2009 6830 6840
86. J. Thaler, C. Ay, N. Mackman, R.M. Bertina, A. Kaider, and C. Marosi et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients J Thromb Haemost 10 2012 1363 1370
87. J. Thaler, C. Ay, N. Mackman, S. Metz-Schimmerl, J. Stift, and A. Kaider et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features Eur J Clin Invest 43 2013 277 285
88. J.I. Zwicker, H.A. Liebman, K.A. Bauer, T. Caughey, F. Campigotto, and R. Rosovsky et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study) Br J Haematol 160 2013 530 537
89. R. Kanz, T. Vukovich, R. Vormittag, D. Dunkler, C. Ay, and J. Thaler et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein J Thromb Haemost 9 2011 57 63
90. A. Palumbo, S.V. Rajkumar, M.A. Dimopoulos, P.G. Richardson, J. San Miguel, and B. Barlogie et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423
91. D. Farge, C. Durant, S. Villiers, A. Long, A. Mahr, and M. Marty et al. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients Thromb Res 125 Suppl 2 2010 S108 S116
92. A.Y.Y. Lee, and E.A. Peterson Treatment of cancer-associated thrombosis Blood 122 2013 2310 2317
93. E.A. Akl, S. Rohilla, M. Barba, F. Sperati, I. Terrenato, and P. Muti et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review Cancer 113 2008 1685 1694
94. F.F. Van Doormaal, G.E. Raskob, B.L. Davidson, H. Decousus, A. Gallus, and A.W.A. Lensing et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials Thromb Haemost 101 2009 762 769
95. A.Y.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, and M. Prins et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153
96. R.D. Hull, G.F. Pineo, R.F. Brant, A.F. Mah, N. Burke, and R. Dear et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 2006 1062 1072
97. G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, and P. Solal-Celigny et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 2002 1729 1735
98. P. Debourdeau, I. Elalamy, A. de Raignac, P. Meria, J.M. Gornet, and Y. Amah et al. Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer Off J Multinatl Assoc Support Care Cancer 16 2008 1333 1341
99. S.R. Deitcher, C.M. Kessler, G. Merli, J.R. Rigas, R.M. Lyons, and J. Fareed et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period Clin Appl Thromb Off J Int Acad Clin Appl Thromb 12 2006 389 396
100. C. Kearon, and E.A. Akl Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism Blood 123 2014 1794 1801
101. K.M. Mikkola, S.R. Patel, J.A. Parker, F. Grodstein, and S.Z. Goldhaber Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer Am Heart J 134 1997 603 607
102. D.M. Sella, and W.A. Oldenburg Complications of inferior vena cava filters Semin Vasc Surg 26 2013 23 28
103. P.D. Stein, F. Matta, and M.J. Sabra Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism Am J Med 126 2013 819 824
104. Muriel A, Jiménez D, Aujesky D, Bertoletti L, Decousus H, Laporte S, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. Epub 2014 Feb 24. 10.1016/j.jacc.2014.01.058. Available from: www.sciencedirect.com/science/article/pii/S0735109714011711.
105. F. Schmidt, C. Faul, J. Dichgans, and M. Weller Low molecular weight heparin for deep vein thrombosis in glioma patients J Neurol 249 2002 1409 1412
106. E. Altschuler, H. Moosa, R.G. Selker, and F.T. Vertosick Jr The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors Neurosurgery 27 1990 74 76 (discussion 77)
107. J.M. Levin, D. Schiff, J.S. Loeffler, H.A. Fine, P.M. Black, and P.Y. Wen Complications of therapy for venous thromboembolic disease in patients with brain tumors Neurology 43 1993 1111 1114
108. D. Schiff, and L.M. DeAngelis Therapy of venous thromboembolism in patients with brain metastases Cancer 73 1994 493 498
109. J.T. Jo, D. Schiff, and J.R. Perry Thrombosis in Brain Tumors Semin Thromb Hemost 40 2014 325 331
110. M. Carrier, A.A. Khorana, J.I. Zwicker, S. Noble, and A.Y.Y. Lee Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH J Thromb Haemost 11 2013 1760 1765
111. A.Y.Y. Lee Treatment of established thrombotic events in patients with cancer Thromb Res 129 Suppl 1 2012 S146 S153
112. M. Carrier, G. Le Gal, R. Cho, S. Tierney, M. Rodger, and A.Y. Lee Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients J Thromb Haemost 7 2009 760 765
113. K.J. Savage, P.S. Wells, V. Schulz, D. Goudie, B. Morrow, and M. Cruickshank et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity Thromb Haemost 82 1999 1008 1010
114. M.J. Kovacs, S.R. Kahn, M. Rodger, D.R. Anderson, R. Andreou, and J.E. Mangel et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study) J Thromb Haemost 5 2007 1650 1653
115. H. Tran, M. Arellano, A. Chamsuddin, C. Flowers, L.T. Heffner, and A. Langston et al. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters Leuk Lymphoma 51 2010 1473 1477
116. D.A. Frank, J. Meuse, D. Hirsch, J.G. Ibrahim, and A.D. van den Abbeele The treatment and outcome of cancer patients with thromboses on central venous catheters J Thromb Thrombolysis 10 2000 271 275
117. A. Pucheu, M. Dierhas, B. Leduc, I. Sillet-Bach, S. Lefort, and W. Assaf et al. [Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis] Bull Cancer (Paris) 83 1996 293 299
118. J. Schindler, R.D. Bona, H.H. Chen, J.M. Feingold, R.L. Edwards, and P.J. Tutschka et al. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue Clin Appl Thromb Off J Int Acad Clin Appl Thromb 5 1999 25 29
119. A.T. Cohen, V.F. Tapson, J.-F. Bergmann, S.Z. Goldhaber, A.K. Kakkar, and B. Deslandes et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study Lancet 371 2008 387 394
120. E.A. Akl, I. Terrenato, M. Barba, F. Sperati, E.V. Sempos, and P. Muti et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis Arch Intern Med 168 2008 1261 1269
121. E.A. Akl, I. Terrenato, M. Barba, F. Sperati, P. Muti, and H.J. Schünemann Extended perioperative thromboprophylaxis in patients with cancer. A systematic review Thromb Haemost 100 2008 1176 1180
122. V.F. Tapson, H. Decousus, M. Pini, B.H. Chong, J.B. Froehlich, and M. Monreal et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism Chest 132 2007 936 945
123. A.K. Kakkar, M. Levine, H.M. Pinedo, R. Wolff, and J. Wong Venous thrombosis in cancer patients: insights from the FRONTLINE survey The Oncologist 8 2003 381 388
124. S.R. Kahn, A. Panju, W. Geerts, G.F. Pineo, L. Desjardins, and A.G.G. Turpie et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada Thromb Res 119 2007 145 155
125. C.J. Pannucci, E.Y. Chang, and E.G. Wilkins Venous thromboembolic disease in autogenous breast reconstruction Ann Plast Surg 63 2009 34 38
126. E.A. Akl, S.R. Vasireddi, S. Gunukula, M. Barba, F. Sperati, and I. Terrenato et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 2011 (CD006649.)
127. P. Mismetti, S. Laporte, J.Y. Darmon, A. Buchmüller, and H. Decousus Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery Br J Surg 88 2001 913 930
128. M.H. Einstein, E.A. Pritts, and E.M. Hartenbach Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review Gynecol Oncol 105 2007 813 819
129. D. Bergqvist, U.S. Burmark, P.A. Flordal, J. Frisell, T. Hallböök, and M. Hedberg et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients Br J Surg 82 1995 496 501
130. D. Bergqvist, G. Agnelli, A.T. Cohen, A. Eldor, P.E. Nilsson, and A. Le Moigne-Amrani et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 2002 975 980
131. M.S. Rasmussen, L.N. Jorgensen, P. Wille-Jørgensen, J.D. Nielsen, A. Horn, and A.C. Mohn et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study J Thromb Haemost 4 2006 2384 2390
132. I. Lausen, R. Jensen, L.N. Jorgensen, M.S. Rasmussen, K.M. Lyng, and M. Andersen et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis Eur J Surg Acta Chir 164 1998 657 663
133. V.V. Kakkar, J.L. Balibrea, J. Martínez-González, P. Prandoni CANBESURE Study Group Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study J Thromb Haemost 8 2010 1223 1229
134. A.G. Turpie, J. Hirsh, M. Gent, D. Julian, and J. Johnson Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control Arch Intern Med 149 1989 679 681
135. L.D. Dickinson, L.D. Miller, C.P. Patel, and S.K. Gupta Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors Neurosurgery 43 1998 1074 1081
136. G.L. Maxwell, I. Synan, R. Dodge, B. Carroll, and D.L. Clarke-Pearson Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial Obstet Gynecol 98 2001 989 995
137. J.F. Collen, J.L. Jackson, A.F. Shorr, and L.K. Moores Prevention of venous thromboembolism in neurosurgery: a metaanalysis Chest 134 2008 237 249
138. M. Carrier, A.A. Khorana, P. Moretto, G. Le Gal, R. Karp, and J.I. Zwicker Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer Am J Med 127 2014 82 86 (e1)
139. S.K. Haas, M. Freund, D. Heigener, L. Heilmann, B. Kemkes-Matthes, and G.-F. von Tempelhoff et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer Clin Appl Thromb Off J Int Acad Clin Appl Thromb 18 2012 159 165
140. M. Verso, G. Gussoni, and G. Agnelli Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies J Thromb Haemost 8 2010 1649 1651
141. H. Riess, U. Pelzer, G. Deutschinoff, B. Opitz, M. Stauch, and S. Reitzig et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial [Abstract] J Clin Oncol (ASCO annual meeting abstracts) 27 Suppl 18s 2009 (Abstract LBA4506)
142. U. Pelzer, A. Hilbig, J.M. Stieler, M. Bahra, M. Sinn, and B. Gebauer et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial BMC Cancer 14 2014 204
143. A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, and F. Lofts et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Eur J Cancer 48 2012 1283 1292
144. S.L. Perry, C. Bohlin, D.A. Reardon, A. Desjardins, A.H. Friedman, and H.S. Friedman et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients J Neurooncol 95 2009 129 134
145. A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano, and F. Patriarca et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial J Clin Oncol 29 2011 986 993
146. A. Larocca, F. Cavallo, S. Bringhen, F. Di Raimondo, A. Falanga, and A. Evangelista et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 2012 933 939
147. B. Meister, G. Kropshofer, A. Klein-Franke, A.M. Strasak, J. Hager, and W. Streif Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia Pediatr Blood Cancer 50 2008 298 303
148. L. Mitchell, M. Andrew, K. Hanna, T. Abshire, J. Halton, and J. Wu et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study Thromb Haemost 90 2003 235 244
149. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
150. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
151. EINSTEIN Investigators, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, and H. Decousus et al. Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
152. EINSTEIN-PE Investigators, H.R. Büller, M.H. Prins, Lensin AWA, H. Decousus, and B.F. Jacobson et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
153. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
154. Hokusai-VTE Investigators, H.R. Büller, H Décousus, M.A. Grosso, M. Mercuri, and S. Middeldorp et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
155. M.N. Levine, C. Gu, H.A. Liebman, C.P. Escalante, S. Solymoss, and D. Deitchman et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer J Thromb Haemost 10 2012 807 814